First-in-human study of CAR T cell therapy with new binding mechanism shows promising early data
Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center. The findings were published today in Molecular Cancer and presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 2096).
Making CD19 CAR T cell therapy more effective for more patients
CAR T cell therapy has revolutionized treatment for many people with blood cancers who had run out of other treatment options. While some patients experience long-term responses to CAR T cell therapy, it doesn’t work–or the cancer eventually returns–for others. The CD19 CAR T cell therapies that are currently approved all target CD19 through the same epitope (FMC63). To try and make CD19 CAR T cell therapy more effective for more patients, Marco Ruella, MD, an assistant professor of Hematology-Oncology and Scientific Director of the Lymphoma Program, and his research team, along with the Korean company AbClon Inc, co-developed a CAR T product (AT101), using cells originating from the same patient, that targets CD19 through a different epitope, located closer to the cell membrane, via a novel antibody (h1218). In preclinical studies, the team previously demonstrated that h1218-CART19 had decreased T cell exhaustion and improved control compared to FMC63-CART19.
The Phase I first-in-human clinical trial (NCT05338931) was conducted in South Korea and enrolled 12 patients with relapsed or refractory B cell non-Hodgkin’s lymphoma (NHL). The study was designed to increase the dose level of AT101 after safety was confirmed in the first six patients. After a median follow-up of 6.5 months, all six patients who received dose level 2 or higher experienced a complete response and their cancer has not relapsed.
“We’ve learned that the way you design your CAR really matters. Designing a different CAR might drastically change the way the T cells work, potentially allowing that CAR T cell product to work where other CAR T cell products have failed,” Ruella said. “We were not expecting such a drastic early difference in this study. The CART19 products that are already FDA-approved are very effective, and it’s not easy to do better. While there is not a randomized trial of this product yet, the initial results seem very promising, and we look forward to moving into the planned Phase II portion of the study.”
The drug was found to be safe, with manageable side effects, including cytokine-release syndrome in four patients and immune-cell-related neurotoxicity syndrome in three patients. One patient experienced grade 3 sepsis that resolved; the same patient later developed fatal neutropenic septic shock outside the dose-limiting toxicity time frame.
The Phase I study enrolled patients who had not previously received any other CAR19 therapy. In the Phase II expansion, the study will also include patients who have previously received CAR19 therapy.
Editor’s Note: The study was funded by AbClon Inc; Ruella is a paid consultant for the company and has a Sponsored Research Agreement with them.
Yunlin Zhang, MS, a research specialist in Ruella’s lab, presented the findings in a poster session on Saturday, Dec. 9, from 5:30 to 7:30 p.m. PT in the San Diego Convention Center Halls G-H.
New KIR-CAR T cell therapy shows promise in solid cancers
An early report of a new type of CAR T cell therapy, called KIR-CAR, was shared in a Clinical Trial Plenary session at the AACR Annual Meeting 2026.
Penn, CHOP team awarded Breakthrough Prize for blindness gene therapy
Jean Bennett, Albert Maguire, and Kathy High honored for trailblazing work on the first FDA-approved gene therapy for an inherited condition.
Penn Medicine at the AACR Annual Meeting 2026
Penn Medicine researchers will present advances in CAR T cell therapy, cancer interception, prevention, and more at the 2026 AACR Annual Meeting.
CRISPR-based platform pinpoints drivers of leukemia in patient cells
A new toolkit allows researchers to test potential cancer targets directly in patient-leukemia cells.
Gene therapy ‘switch’ may offer non-addictive pain relief
A new gene therapy may offer pain relief without addiction, targeting only pain signals and leaving the rest of the brain untouched.
Improving treatment for an autoimmune bleeding condition
More than half of patients who received an experimental treatment for immune thrombocytopenia maintained safe platelet counts without bleeding episodes for at least one year.
Delayed toxicities after CAR T cell therapy for myeloma
Research presented at ASH 2025 sheds light on serious side effects that appear weeks or months after CAR T cell therapy for multiple myeloma.
Penn Medicine at the 2025 ASH Annual Meeting
Penn Medicine researchers will present the latest advances in blood cancer and classical hematology research at the 2025 ASH Annual Meeting.
New CAR T strategy targets most common form of heart disease
CAR T cell therapy could be a highly effective tool against atherosclerosis, a common condition that leads to heart attacks and stroke.
Penn hematologist elected to lead American Society of Hematology
Alison Loren, MD, MSCE, division chief of Hematology-Oncology, has been elected to serve as the vice president of the American Society of Hematology.